Corcept Therapeutics - CORT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $33.79
  • Forecasted Upside: 51.10%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$22.36
▼ -0.22 (-0.97%)

This chart shows the closing price for CORT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Corcept Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CORT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CORT

Analyst Price Target is $33.79
▲ +51.10% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is $33.79, with a high forecast of $47.50 and a low forecast of $25.00. The average price target represents a 51.10% upside from the last price of $22.36.

This chart shows the closing price for CORT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in Corcept Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/27/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/22/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2024Truist FinancialBoost TargetBuy ➝ Buy$36.00 ➝ $42.00Low
1/2/2024HC WainwrightLower TargetBuy ➝ Buy$34.00 ➝ $28.00Low
12/13/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$37.00 ➝ $38.00Low
11/6/2023Truist FinancialUpgradeHold ➝ Buy$29.00 ➝ $38.00Low
11/2/2023HC WainwrightBoost TargetBuy ➝ Buy$32.00 ➝ $34.00Low
10/2/2023Truist FinancialReiterated RatingHold ➝ Hold$29.00Low
8/25/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$34.00 ➝ $35.00Low
8/3/2023Truist FinancialBoost TargetHold ➝ Hold$26.00 ➝ $29.00Low
8/3/2023Piper SandlerBoost TargetOverweight ➝ Overweight$27.00 ➝ $31.00Low
8/3/2023LADENBURG THALM/SH SHBoost Target$44.00 ➝ $47.50Low
8/3/2023HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $32.00Low
5/26/2023Truist FinancialLower Target$28.00 ➝ $26.00Low
4/11/2023SVB LeerinkReiterated RatingMarket Perform$25.00Low
4/11/2023SVB SecuritiesInitiated CoverageMarket Perform$25.00Low
4/4/2023Piper SandlerInitiated CoverageOverweight$27.00Low
3/8/2023Canaccord Genuity GroupLower TargetBuy$33.00 ➝ $32.00Low
3/1/2023HC WainwrightReiterated RatingBuy$30.00Low
2/15/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$35.00 ➝ $22.00Low
12/9/2022HC WainwrightLower TargetBuy$33.00 ➝ $30.00Low
8/9/2022Truist FinancialDowngradeHoldN/A
8/4/2022HC WainwrightBoost TargetBuy$29.00 ➝ $33.00N/A
8/1/2022Truist FinancialDowngradeBuy ➝ Hold$30.00Low
7/27/2022Jefferies Financial GroupUpgradeHold ➝ Buy$21.00 ➝ $35.00Low
2/16/2022HC WainwrightReiterated RatingBuy$29.00High
2/2/2022Canaccord Genuity GroupInitiated CoverageBuy$30.00Medium
1/28/2022Truist FinancialInitiated CoverageBuy$30.00High
7/30/2021HC WainwrightReiterated RatingBuyMedium
6/23/2021HC WainwrightLower TargetBuy$32.00 ➝ $29.00Low
6/22/2021UBS GroupReiterated RatingPositiveHigh
11/27/2020HC WainwrightBoost TargetPositive ➝ Buy$22.00 ➝ $32.00Low
11/4/2020HC WainwrightBoost TargetBuy$18.00 ➝ $22.00High
8/5/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$16.00High
2/21/2020Cantor FitzgeraldReiterated RatingNeutral$14.00 ➝ $15.00Low
9/24/2019Jefferies Financial GroupInitiated CoverageBuy$20.00Medium
9/6/2019HC WainwrightInitiated CoverageBuy$18.00Low
5/1/2019Cantor FitzgeraldReiterated RatingHold$14.00Low
2/26/2019Cantor FitzgeraldSet TargetHold$14.00High
(Data available from 2/21/2019 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2023
  • 14 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/25/2023
  • 14 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/24/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/24/2023
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2023
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2023
  • 11 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
1/22/2024
  • 20 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/21/2024

Current Sentiment

  • 20 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Corcept Therapeutics logo
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $22.36
Low: $22.28
High: $22.56

50 Day Range

MA: $25.70
Low: $21.10
High: $32.88

52 Week Range

Now: $22.36
Low: $17.86
High: $34.28

Volume

55,979 shs

Average Volume

2,078,298 shs

Market Capitalization

$2.31 billion

P/E Ratio

23.54

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Corcept Therapeutics?

The following sell-side analysts have issued research reports on Corcept Therapeutics in the last year: Canaccord Genuity Group Inc., HC Wainwright, LADENBURG THALM/SH SH, Piper Sandler, StockNews.com, SVB Leerink LLC, SVB Securities, and Truist Financial Co..
View the latest analyst ratings for CORT.

What is the current price target for Corcept Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Corcept Therapeutics in the last year. Their average twelve-month price target is $33.79, suggesting a possible upside of 51.1%. LADENBURG THALM/SH SH has the highest price target set, predicting CORT will reach $47.50 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $25.00 for Corcept Therapeutics in the next year.
View the latest price targets for CORT.

What is the current consensus analyst rating for Corcept Therapeutics?

Corcept Therapeutics currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CORT.

What other companies compete with Corcept Therapeutics?

How do I contact Corcept Therapeutics' investor relations team?

Corcept Therapeutics' physical mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company's listed phone number is (650) 327-3270 and its investor relations email address is [email protected]. The official website for Corcept Therapeutics is www.corcept.com. Learn More about contacing Corcept Therapeutics investor relations.